Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Entelon (vitis vinifera extract) is a botanical drug product developed by Hanlim Pharm, primarily composed of proanthocyanidins extracted from grape seeds. It is marketed in South Korea for the treatment of venous insufficiency and as an adjuvant therapy for breast cancer-related lymphadenoma. The drug is also being evaluated in Phase III clinical trials for the treatment of knee osteoarthritis, where it is compared against celecoxib. Mechanistically, the extract exerts anti-inflammatory effects by downregulating interleukin-1 alpha (IL-1α) and modulating the MEK/ERK signaling pathway, which are involved in the progression of inflammatory joint diseases and vascular disorders.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on vitis vinifera extract.